Achilles Therapeutics is looking for a meaty $176 million initial public offering for its next-gen immuno-oncology work. It has already trod a strong financial path, and, back in 2019, Achilles raised an impressive £100 million ($120 million) series B round, which at the time set it up to run human proof-of-concept studies of its personalized T-cell therapies in two types of solid tumors. Two years down the line, and it now has its leading drug, ATL001, in the clinic: one test is in non-small cell lung cancer, followed up with a green light to run a trial in melanoma patients. Source: Fierce Biotech 26/3/2021